BetaLife Pte. Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BetaLife Pte. Ltd. - overview
Established
2020
Location
-, -, Singapore
Primary Industry
Biotechnology
About
Founded in 2020 and based in Singapore, BetaLife Pte. Ltd. is a stem cell therapy company providing iPSC-based regenerative medicine technology solutions. The company was founded by Adrian Teo, Natasha Ng, and Lim Kah Meng.
In June 2022, BetaLife Pte. Ltd. raised USD 0. 80 million in seed funding from individuals and unspecified investors.
BetaLife offers an Agency for Science, Technology and Research (A*STAR) platform that develops stem cell-based regenerative therapeutic solutions for diabetes patients. The company produces hiPSC-based pancreatic islet cells for treating type 1 diabetes (T1D) and type 2 diabetes (T2D) patients. The products and solutions offered by the company include iPSCs (induced pluripotent stem cells) from healthy individuals; human iPSC-derived pancreatic cells for diabetes patients; and many more.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.betalife.sg
Verticals
HealthTech, Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.